-Sazdanić (2011): HLA II class antigens and susceptibility to coeliac disease. Vol 43, No. 3,[517][518][519][520][521][522][523][524][525][526] Coeliac disease (CD) is a systemic autoimmune, complex and multifactorial disorder, which is caused by interactions between genetic and environmental factors. The only established genetic risk factors so far are the human leucocyte antigens. The aim of this study was to assess the distribution of II class human leukocyte antigens (HLA) in patients with coeliac disease and to investigate the susceptibility to coeliac disease in family members. We typed HLA DR and DQ antigens in 37 patients from Vojvodina with coeliac disease, 23 first-degree relatives, and 210 controls, serologically using standard lymphocytotoxicity technique. HLA DQ5(1), DQ6(1), DR11(5), DQ7(3), DQ2 and DR15(2) were the most common antigens in the control group. Frequency of HLA DQ2, DR3 and DR7 was higher in CD patients than in the control group. The relative risks for HLA 518 GENETIKA, Vol. 43, No.3,517 -526, 2011 DQ2, DR3 and DR7 were 4.846, 6.986 and 2.106, respectively, while positive association was found between HLA DQ2 and DR3 and CD. Frequency of HLA DQ2, DR3 and DR16(2) was higher in first-degree relatives than in the control group while a positive association was found between HLA DQ2 and DR3. A negative association was found between HLA DQ5(1) and DQ6(1) in coeliac patients from Vojvodina and their relatives, in addition to HLA DR11(5) in the group of relatives (RR=0.363,PF=0.232). These findings indicate the impact of the HLA testing for CD in clinical practice in order to rule out the possibility to CD in doubtful cases or in at-risk subjects.
INTRODUCTION
Coeliac disease (CD) is a common, familial, autoimmune, multifactorial gastrointestinal disease defined as a permanent gluten-sensitive enteropathy characterized by malabsorption and mucosal injury of the small bowel. Symptomatology varies widely from absolute absence of symptoms to pronounced clinical, gastrointestinal, or extradigestive manifestations. It is caused by sensitivity to the dietary protein gluten, which is present in wheat, rye and barley. Symptoms include growth failure, abdominal pain, and diarrhea (VIDALES et al., 2004; NEUHAUSEN et al., 2001) . CD can be present at any age and in different clinical forms such as classical, atypical, silent, or latent CD. Classical CD is characterized by chronic diarrhea, abdominal distention, vomiting, muscle wasting and failure to thrive. The timing of presentation of CD may be dependent on the amount and timing of gluten introduction to the diet. Atypical CD presents with extraintestinal manifestations such as unexplained iron deficiency anemia, short stature, osteoporosis, pubertal delay, dental enamel defects, and abnormalities in liver function tests (KULOGLU et al., 2008) . Recent accurate epidemiologic studies have revealed that CD affects approximately 1% of the general population, both in Europe and in North America. The prevalence of the disease increases among patients with anemia or autoimmune diseases, with short stature, or with Down, Turner, or Williams syndrome. Moreover, CD clusters in families with a prevalence among first-degree relatives ranging from 2.8% to 17.2% in different series (MEGIORNI et al., 2009) .CD shares many features with autoimmune disorders in general, such as a polygenic mode of inheritance, a strong association with HLA-DQ2 and HLA-DQ8 antigens, the production of a local inflammatory response (lymphocyte infiltration and cytokine production), the presence of autoantibodies in the circulation, female preponderance, and an association with other autoimmune diseases (KUMAR et al., 2001) . Coeliac disease is caused by an inappropriate intestinal immune response to wheat gluten (consisting of the gliadin and glutenin subcomponents) and the related proteins of rye and barley. Patients with coeliac disease have gluten-reactive CD4 + T cells in their small intestinal mucosa, but healthy controls do not. Most patients with coeliac disease carry the HLA-DQ2 variant DQ2.5, which is encoded by the DQA1*0501 and DQB1*0201 genes of the DR3-DQ2 haplotype. Most of the few remaining patients express HLA-DQ8. The gluten-reactive T cells of patients with coeliac disease recognize a diverse set of gluten epitopes presented in context of DQ2.5 or DQ8 MHC molecules but not in the context of other MHC class II molecules expressed by the patients. 'Preferential' presentation of gluten peptides by the DQ2.5 and DQ8 molecules thus seems to explain the association of HLA with celiac disease (FALLANG et al., 2009) . The genetic influence in the pathogenesis of coeliac disease is indicated by its familial occurrence. Coeliac disease does not develop unless a person has alleles that encode for HLA-DQ2 or HLA-DQ8 proteins, products of two of the HLA genes. However, many people, most of whom do not have coeliac disease, carry these alleles; thus, their presence is necessary but not sufficient for the development of the disease. Studies in siblings and identical twins suggest that the contribution of HLA genes to the genetic component of coeliac disease is less than 50%. Several non-HLA genes that may influence susceptibility to the disease have been identified, but their influence has not been confirmed (GREEN and CELLIER, 2007) . In this study, we investigated the frequency of the DR and DQ antigens in individuals with coeliac disease, their first-degree relatives and normal control subjects. We also determined a significant risk and protective factors in investigated groups. In this study, we aimed to determine whether measuring the atrisk HLA antigens can assist in diagnosis of coeliac disease in patients and in their relatives without coeliac disease.
MATERIALS AND METHODS

Subjects and methods
A total of 37 coeliac patients from Vojvodina were studied. Of all patients 70.27% were female and 29.72% male. At-risk subjects were first-degree relatives of patients with CD who presented with CD-associated symptoms (diarrhea, abdominal pain, and constipation) or without it. Two hundred and ten randomly selected healthy individuals from Vojvodina population served as healthy control subjects. The II class HLA typing was performed by microlymphocytotoxicity assay using T and B cells separated by monoclonal antibody labeled immunomagnetic particles (IMB) (VARTDAL et al.,1986) .
Statistical analysis
HLA DR and DQ phenotype frequencies were calculated by direct counting method, using following formula: A= n/N, where n is number of persons with a given antigen and N is total number of persons studied (SHEN et al.,2008) . Relative risk (RR) for measuring strenght of association with each II class HLA antigen was calculated by the Woolf′s method (ARMITAGE et al., 2002) , by using following When RR was higher than 1, we calculated the etiologic fraction, while for RR values less than 1, we calculated the preventive fraction. When several antigens with different allele frequencies are associated with the same disease, it is not possible to estimate which of them is more strongly associated with the disease itself solely by means of relative risk; that depends directly on the frequency of the antigen allele. A more accurate estimate of the strength of an association has been made by the calculation of the so-called etiologic fraction that detects among the different antigens associated with a certain disease, which antigen has the stronger genetic association with a hypothetical disease allele. The etiologic fraction (EF) or population attributable risk, was calculated according to the Green′s method, using following formula:
, where FAD is the frequency of a given HLA antigen in the subgroup of patients and FAP is the frequency of HLA antigen in the control group. The preventive fraction (PF), that gives the percentage of cases that can be prevented if a population is exposed to an intervention, compared to an unexposed population, was calculated according to following formula:
, where RR is relative risk and f is the frequency of HLA antigen in the subgroup of patients (GREEN et al.,1982; CORAZZA et al., 1985) .
The association was considered positive if the calculated EFs were higher than 0.15 and negative if calculated PFs were more than 0.15. The Pearson χ 2 goodness-of-fit test was used to valuate Hardy-Weinberg genetic equilibrium for phenotypic data (ARMITAGE, et al., 2002) .
RESULTS
The distribution of HLA DR and DQ types in CD patients, their first-degree realetives and controls is shown in Table 1. In the control group, HLA DQ5(1) (78.5%),DQ6(1) (45.7%), DR11(5) (36.6%), DQ7(3) (36.1%), DQ2(30%) and DR15(2) (29%) were the most common HLA types observed in II class HLA groups, respectively. In CD patients, HLA DQ2 (67.5%), DR3 (48.6%), DQ6(1) (32.4%), DQ7(3) (29.7%), DR7, DR11(5) and DQ15(2) with the same frequency (24.3%) were the most common HLA types observed in HLA groups DR and DQ, respectively.
In the group of first-degree relatives, the most common DR and DQ antigens were also DQ2 and DR3, both observed in 47.8% of relatives, following with DQ6(1) (34.7%), DQ7(3) and DR15(2) (26%), respectively. All of the HLA loci in CD patients, their relatives and controls were consistent with Hardy-Weinberg equilibrium. The results showing relative risk, etiologic and preventive fraction are ilustrated in Table 2 .
Our results demonstrated that there were several HLA class II antigens associated with an increased risk of developing coeliac disease, such as: DQ2 (5) (RR=0.363, PF=0.232) in the group of relatives, which reveals that they could be a possible protective factors in investigated groups. DISCUSSION The genesis and development of CD depend on both genetic and environmental factors. Coeliac disease is an immune-mediated disease where genetic predisposition plays a key role and considerable progress has been made recently in identifying genes that are responsible for CD predisposition. It is well known that CD is strongly associated with specific HLA class II genes known as HLA-DQ2 and HLA-DQ8 located on chromosome 6p21. Approximately 95% of CD patients express HLA-DQ2, and the remaining patients are usually HLA-DQ8 positive. However, the HLA-DQ2 allele is common and is carried by approximately 30% of Caucasian individuals. Thus, HLA-DQ2 or HLA-DQ8 is necessary for disease development but is not sufficient for disease development; its estimated risk effect is only 36-53% (MOUSTAKAS et al., 2000; VIDALES et al., 2004; LIU et al., 2002; VOLTA and VILLANACCI, 2011; MAKI et al., 2003) . The genetic susceptibility to CD is confirmed by its high familial incidence (about 10% of first degree relatives of coeliac patients are affected by the disease) and by its strict linkage with some human leukocyte antigen (HLA) class 2 alleles (up to 95% coeliacs are HLA-DQ2 positive with the typical heterodimer DQA1*0501/DQB1*0201, whereas the remaining 5% are HLA-DQ8 positive HLA-DQB1*0302, (VOLTA and VILLANACCI, 2011) . Despite numerous population studies supporting the idea that the HLA region plays the main role in the genetic susceptibility to many multifactorial autoimmune diseases, not enough familial data in the population of Vojvodina are available to quantify the relative contribution of HLA and other genes in the development of these diseases. We presented here a group of paediatric coeliac cases and their relatives together with data from the literature, with the double aim to assess the HLA role on the increased risks of disease in the CD patients and their siblings and to find out the II HLA class specificities that may play a true protective role for the development of coeliac disease. Our results showed that DR3, DQ2 and DR7 were found in higher frequencies in coeliac patients and DR3 and DQ2 in their relatives. Firstly, the higher frequency of HLA B8 in celiac patients has been reported. Later, it was observed that frequency of HLA DR3 is also increased and that the association with HLA B8 simply reflected the linkage disequilibrium between the alleles that coded for these antigens (KULOGLU et al., 2008) . In our study, frequency of HLA DQ2 in CD was 67.5% and 47.8% in relatives, which is similar to other reports (MAKI et al., 2003; KULOGLU et al., 2008; PETRONZELLI et al., 1997) . Our study confirmed the strong association of CD patients and their relatives with HLA DQ2 and DR3, which is also in accordance with the results of previous studies (PETRONZELLI et al., 1997; MAKI et al., 2003; VOLTA and VILLANACCI, 2011) . The association between HLA DR3/DR7 and CD is explained by the linkage disequilibrium of these alleles with DQ2 allele (CORAZZA et al., 1985; VOJVODIĆ and ADEMOVIĆ-SAZDANIĆ, 2009; VOJVODIĆ and ADEMOVIĆ-SAZDANIĆ, 2011a; VOJVODIĆ and ADEMOVIĆ-SAZDANIĆ, 2011b) . Although in our study, the RR for HLA DR7 in coeliac patients was higher than 1, we did not demonstrate an association between DR7 and CD (EF=0.126). The difference of HLA distribution and consequently RR value, may be associated with genetic heterogeneity and geographic region.The positive association between DR3 and DQ2 and susceptibility to coeliac disease is also found in the group of first-degree relatives: for DQ2 (RR=1.230, EF=0.254) and for DR3 (RR=1.821, EF=0.351), but unlike in CD patients, in the group of relatives, DR3 has the strongest genetic association with coeliac disease, since in CD patients EF=0.361 for DR3 and EF=0.535 for DQ2. This findings confirm the previous reports that the first relatives are subjects at risk for CD developing (MEGIORNI et al.,2009; VOLTA and VILLANACCI, 2011; LIU et al., 2002) . Our results have shown the existence of negative association of DQ5(1) and DQ6(1) antigens with coeliac disease patients as well as their relatives. Stronger negative association was found for DQ5(1) than DQ6(1) in both of groups since PF=0.742 and PF=0.727 for DQ5(1) vs PF=0.194 and PF=0.167 for DQ6(1), respectively. Additionally, in the group of first-degree relatives it is observed that DR11(5) has the lower frequency than control group (RR=0.363, PF=0.232) with significant negative association, showing how much are relatives protected from the coeliac disease by these possible protective HLA factors.
CONCLUSION
In conclusion, this study demonstrated that HLA types are important in the development of CD and DR3 and DQ2 were the most frequent antigens in patients with CD and their relatives in Vojvodina. Our study also showed that a relation may exist between possible protective HLA types and disease development. This result confirms that the HLA antigens are an important genetic background to CD and that the detection of HLA II class antigens can help reinforce or exclude the diagnosis of gluten sensitivity.
HLA ANTIGENI II KLASE I PREDISPOZICIJA ZA CELIJAKIJU
Svetlana VOJVODIĆ
1 , Dušica ADEMOVIĆ-SAZDANIĆ 1 Zavod za transfuziju krvi Vojvodine, Novi Sad, Srbija I z v o d Celijakija je sistemski autoimuni, kompleksni i multifaktorijalno uzrokovan poremećaj koji nastaje kao posledica interakcije genetskih i ekoloških faktora. Jedini potvrđeni genetski faktori rizika za sada su humani lukocitni antigeni. Cilj ovog rada je bio da se proceni distribucija II klase humanih leukocitnih antigena (HLA) kod bolesnika sa celijakijom i da ispita predispozicija za nastanak celijakije u članove njihovih porodica. Vršena je tipizacija HLA antigena DR i DQ lokusa kod 37 pacijenata iz Vojvodine obolelih od celijakije, 23 osobe u prvom stepenu srodstva kao i kod 210 zdrave osoba, serološki standardnim mikrolimfocitotoksičnim testom. HLA DQ5(1), DQ6(1), DR11(5), DQ7(3), DQ2 i DR15 (2) su najčešće zastupljeni antigeni u kontrolnoj grupi. Učestalost HLA DQ2, DR3 i DR7 je bila veća u bolesnika sa celijakijom nego u kontrolnoj grupi. Relativni rizik za HLA DQ2, DR3 i DR7 iznosi 4.846, 6.986 i 2.106, dok je pozitivna udruženost uočena između HLA DQ2 i DR3 i celijakije. Učestalost HLA DQ2, DR3 i DR16(2) bila je veća u osoba u prvom stepenu srodstva sa obolelim od celijakije nego u kontrolnoj grupi, dok je pozitivna asocijacija uočena između HLA DQ2 i DR3. Negativne asocijacije su uočene između HLA DQ5(1) i DQ6(1) i bolesnika sa celijakijom sa teritorije Vojvodine i njihovih srodnika, kao i HLA DR11(5) u grupi srodnika (RR = 0.363, RF = 0.232). Ovi nalazi ukazuju na značaj testiranja HLA antigena i njenu primenu u kliničkoj praksi kod osoba sa ispoljenim simptomima bolesti kao i mogućnost utvrđivanja rizika za nastanak bolesti kod članova njihovih familija.
